Perinatal morbidity and mortality of children born to mothers with chronic kidney disease.

INTRODUCTION: Chronic kidney disease (CKD) associated with pregnancy increases the risk of maternal and fetal complications. OBJECTIVE: To determine perinatal morbidity and mortality of children born to mothers with mild and moderate CKD during pregnancy. METHODS: Retrospective study of medical records of women with mild and moderate CKD during pregnancy cared for at La Raza National Medical Center between 2010 and 2016. RESULTS: There were 142 patients, 99 (69.72%) with mild CKD and 43 (30.28%) with moderate CKD; 79 neonates (55.63%) reached full term, 28 (19.71%) had growth restriction; 44 (30.98%), low birth weight and 54 (38.02%) were admitted to the neonatal intensive care unit (NICU); and four women (4.04%) had an abortion; in four (2.81%), their children had intrauterine death, and in 10 (7.04%), neonatal death. High blood pressure (odds ratio [OR] = 6.93) and hemoglobin < 11 g/dL (OR = 2.48) were risk factors for prematurity. CONCLUSION: A relationship was found between anemia and blood pressure levels and risk for prematurity, low Apgar, and NICU admission.

INTRODUCCIÓN: La enfermedad renal (ER) crónica asociada al embarazo incrementa el riesgo de complicaciones maternas y fetales. OBJETIVO: Determinar la morbilidad y mortalidad perinatal del hijo de madre con enfermedad renal leve y moderada del embarazo. MÉTODOS: Estudio retrospectivo de expedientes de mujeres con ER leve y moderada del embarazo atendidas en el Centro Médico Nacional La Raza entre 2010 y 2016. RESULTADOS: Se trató de 142 pacientes, 99 (69.72 %) con ER leve y 43 (30.28 %) con ER moderada; 79 (55.63 %) neonatos llegaron a término, 28 (19.71 %) presentaron restricción de crecimiento; 44 (30.98 %), peso bajo al nacimiento y 54 (38.02 %) ingresaron a la unidad de cuidados intensivos neonatales; cuatro (4.04 %) mujeres presentaron aborto, en cuatro (2.81 %) sus hijos presentaron muerte intrauterina y en 10 (7.04 %), muerte neonatal. La presión arterial alta (RM = 6.93) y la hemoglobina < 11g/dL (RM = 2.48) constituyeron factores de riesgo para prematurez. CONCLUSIÓN: Se encontró relación entre la anemia y las cifras de tensión arterial como riesgo para prematurez, Apgar bajo e ingreso a unidad de cuidados intensivos neonatales.

Survival of Vascular Accesses in Chronic Hemodialysis Patients.

BACKGROUND/AIMS: Vascular access (VA) is the highest risk factor for blood infections, hospitalization, and mortality of patients undergoing hemodialysis (HD). The risk of mortality while using a catheter is greater than that while using grafts. The objective of this article is to know the survival rate in relation to the type of VA. METHODS: A retrospective cohort of HD patients was studied. The data gathered included age, gender, first VA at the surrogate site, days between the first and second access, number of accesses, and anatomical site of VA placement. Mean differences were estimated using χ2 or Student's t test. Survival was calculated using the Kaplan-Meier curves and included in tables. Statistical significance was established as p < 0.05. The statistical computer software package SPSSw v25 was used for the analysis. RESULTS: A total of 896 patients were included with a mean age of 47.88 years (SD ± 16.52), the duration of the first VA was 398.81 days (±565.79), the mean number of VAs used was 2.26 (±1.15), and the median time undergoing HD was 728.73 days. The duration of catheter placement was 330.42 days, and 728.60 days for fistula use (p = 0.001). The mean number of days of renal replacement was 611.59 days for catheter and 1,495.25 days for internal arteriovenous fistula (IAVF) patients (p = 0.001). CONCLUSIONS: The survival of the initial VA is greater for the IAVF, followed by the tunneled catheters and the lowest by the non-tunneled catheters, which continue to be frequently used in our setting.

COVID-19 pandemic in Mexico: surveillance protocol in intrahospital hemodialysis units. / Pandemia COVID-19 en México: protocolo de vigilancia en unidades de hemodiálisis intrahospitalarias.

On January 30 2020, the World Health Organization (WHO) declared the COVID-19 outbreak as epidemiological emergency. Globally, various guidelines have been published for the safety of patients with chronic kidney disease (CKD) and health personnel working in hemodialysis centers. In Mexico, the prevalence of CKD is 12.2% and 60,000 patients receive some modality of renal replacement therapy at the Instituto Mexicano del Seguro Social (IMSS, Mexican Institute for Social Security). This proposal for action is made in the face of suspected and confirmed cases of COVID-19 in intrahospital hemodialysis units.

El 30 de enero de 2020, la Organización Mundial de la Salud (OMS) declaró el brote de COVID-19 como emergencia epidemiológica. A nivel mundial han surgido diversos lineamientos para la seguridad de los pacientes que padecen enfermedad renal crónica (ERC) y el personal de salud que labora en centros de hemodiálisis. En México, la prevalencia de ERC es de 12.2% y 60 000 enfermos reciben alguna modalidad de terapia de reemplazo renal en el Instituto Mexicano del Seguro Social (IMSS). Se realiza esta propuesta de actuación ante casos sospechosos y confirmados de COVID-19 en unidades de hemodiálisis intrahospitalaria.

[Long-term patient and graft survival in kidney transplant recipients]. / Supervivencia del paciente y del injerto a largo plazo en receptores de trasplante renal.

BACKGROUND: Kidney transplantation is the therapy of choice for patients with chronic renal failure. In Mexico, good short-term results have been reported for graft survival, which is why it was carried out a study in a third level center in Mexico City to broaden these results. OBJECTIVE: To identify long-term results of patient and graft survival. MATERIAL AND METHODS: Retrospective study with first 1600 kidney transplants performed at the Hospital de Especialidades (Specialties Hospital) "Dr. Antonio Fraga Mouret" from La Raza National Medical Center. Patient and graft survival was analyzed at 1, 3, 5, 7 and 10 years. Kaplan Meier survival analysis and log rank test were performed. RESULTS: Between October 1979 and May 2015, 1600 kidney transplants were performed (1473 [92.1%] of living donor and 127 [7.9%] of deceased donor). Graft survival censored for death with functional graft at 1, 3, 5, 7 and 10 years was 95.4, 91.7, 88.2, 86.6 and 85.5%, respectively. Patient survival was 92.7, 90.4, 89.7, 89.4, and 88.9% at 1, 3, 5, 7 and 10 years, respectively. CONCLUSIONS: Long-term patient and graft survival in our center is similar to that reported by other centers at an international level.

INTRODUCCIÓN: el trasplante renal es la terapia de elección en pacientes con insuficiencia renal crónica. En México se reportan buenos resultados a corto plazo, por lo que se realizó un estudio en un centro de tercer nivel de la Ciudad de México para ampliar estos resultados. OBJETIVO: conocer los resultados en supervivencia del paciente e injerto a largo plazo. MATERIAL Y MÉTODOS: estudio retrospectivo con los primeros 1600 trasplantes renales realizados en el Hospital de Especialidades "Dr. Antonio Fraga Mouret" del Centro Médico Nacional La Raza. Se analizó la sobrevida de paciente e injerto a los 1, 3, 5, 7 y 10 años. Se utilizó análisis de supervivencia de Kaplan Meier y prueba de log rank. RESULTADOS: entre octubre de 1979 y mayo de 2015 se realizaron 1600 trasplantes renales (1473 [92.1%] de donante vivo y 127 [7.9%] de donante fallecido). La supervivencia del injerto censurada para muerte con injerto funcional a 1, 3, 5, 7 y 10 años fue de 95.4, 91.7, 88.2, 86.6 y 85.5%, respectivamente, en tanto que la supervivencia del paciente fue de 92.7, 90.4, 89.7, 89.4 y 88.9% a los 1, 3, 5, 7 y 10 años, respectivamente. CONCLUSIONES: la sobrevida de paciente e injerto a largo plazo en este centro es similar a lo reportado en otros centros a nivel internacional.

Mortality in Patients With Chronic Renal Disease Without Health Insurance in Mexico: Opportunities for a National Renal Health Policy.

INTRODUCTION: Despite a systematic increase in the coverage of patients with end-stage renal disease (ESRD) who have received dialytic therapies and transplantation over the past 2 decades, the Mexican health system currently still does not have a program to provide full coverage of ESRD. Our aim was to analyze mortality in patients with ESRD without health insurance. METHODS: This was a prospective cohort study of 850 patients with advanced chronic kidney disease (CKD). Risk factors associated with death were calculated using a Cox's proportional hazards model. We used the statistical package SPSS version 22.0 for data analysis. RESULTS: The mean age of patients was 44.8 ± 17.2 years old. At the time of hospital admission, 87.6% of the population did not have a social security program to cover the cost of renal replacement treatment, and 91.3% of families had an income below US$300 per month. During the 3 years of the study, 28.8% of the cohort patients were enrolled in 1 of Mexico's social security programs. The 3-year mortality rate was of 56.7% among patients without access to health insurance, in contrast to 38.2% of patients who had access to a social security program that provided access to renal replacement therapy (P < 0.001). Risk factor analysis revealed that not having health insurance increased mortality (risk ratio: 2.64, 95% confidence intervals: 1.84-3.79; P = 0.001). CONCLUSION: Mexico needs a coordinated National Kidney Health and Treatment Program. A program of this nature should provide the basis for an appropriate educational and intervention strategy for early detection, prevention, and treatment of patients with advanced chronic kidney disease.

Síndrome cardiorrenal: Nuevas perspectivas / Cardiorenal syndrome: New perspectives

La disfunción cardiaca y la renal coexisten con alta prevalencia. Se ha definido a esta entidad clínica como síndrome cardiorrenal y una de sus características principales es la resistencia al tratamiento. Se han descrito múltiples hipótesis para explicar su fisiopatología, como la desregulación hemodinámica y, recientemente, mecanismos neurohumorales e inmunológicos que intervienen en su desarrollo y perpetuación. Se clasifica de acuerdo con su forma de presentación y componentes fisiopatológicos. Existen distintos enfoques terapéuticos para controlar o limitar el progreso de la enfermedad. Esta revisión discute y analiza la información actual sobre la fisiopatología, la clasificación y el tratamiento de esta entidad.

There is a high prevalence of heart failure associated to kidney failure or viceversa. This association has been defined as a clinical entity: cardiorenal syndrome and one of its main characteristics is the resistance to treatment. Multiple hypotheses have been proposed to explain the pathophysiology of this syndrome, such as hemodynamic deregulation and recently, other neurohormonal and immunological mechanisms involved in the development and perpetuation of this pathology. Classifications have been based on the form of presentation or physiopathological manifestations. Different therapeutic approaches have been proposed to control or limit the progress of this disease. This review discusses and analyzes the current information on pathophysiology, different classifications and treatment.